FDA
-
-
-
-
-
-
-
Celgene (CELG) Receives CHMP Positive Opinion for REVLIMID in Combination With Rituximab for Treatment of Adult Patients With Previously Treated Follicular Lymphoma
-
-
-
-
-
-
-
Data from Ozanimod Clinical Development Program in Relapsing Forms of Multiple Sclerosis to Be Presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
-
-
-
-
-
-
-
GT Biopharma Company Update
-
-
-
-
-
-
-
Celgene (CELG) Announces FDA Approval for REVLIMID in Combination With Rituximab For Treatment of Adults with Previously Treated FL or MZL
-
-
-
-
-
-
-
Celgene Receives European Commission Approvals for REVLIMID® (lenalidomide) and IMNOVID® (pomalidomide)-based Triplet Combination Regimens for Patients with Multiple Myeloma
-
-
-
-
-
-
-
Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Marketing Authorization Application to the European Medicines Agency (EMA) for MDS and Beta-Thalassemia
-
-
-
-
-
-
-
Bristol-Myers Squibb Issues Statement on Celgene’s Settlement with Alvogen on Revlimid® Patent Litigation
-
251,761 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All